AAN 2018: Latest CGRP inhibitor data extend understanding of potential role in migraine prevention

At this year's American Academy of Neurology congress in Los Angeles, updates on all the CGRP inhibitors in late stage development built on previous evidence of their safety and efficacy as migraine therapies.

Galcanezumab reduces migraine days in non responders to previous prophylaxis

Galcanezumab significantly reduces monthly migraine days in patients with episodic and chronic migraine who previously failed on at least two preventive therapies.

Read the full report here »

LIBERTY data confirm erenumab efficacy in migraine patients unresponsive to other preventive therapies

More than twice as many patients had at least a 50% reduction in migraine days with erenumab compared to placebo.

Read the full report here »

Fremanezumab results support flexible dosing

Two subcutaneous dose regimens for fremanezumab have proved equally effective and well tolerated in patients with chronic migraine.

Read the full report here »

Eptinezumab demonstrates further migraine reduction with longer term treatment

Further reductions in migraine risk following third and fourth quarterly infusions of eptinezumab 100mg and 300mg have been reported from the Promise 1 trial in patients with episodic migraine.

Read the full report here »

Erenumab has no adverse effect on exercise time in patients with stable angina

Exercise test results in patients with stable angina treated with erenumab suggest that CGRP inhibition does not aggravate myocardial ischaemia.

Read the full report here »